(12-365) Evaluation of Hypersensitivity Reactions with Daratumumab Hyaluronidase First Dose Administration Within 3-Hour Monitoring Window

Wednesday, December 10, 2025

2:00 PM - 3:00 PM

Location: Bayside A, Level 1

Residency Program: Thomas Jefferson University Hospital
Residency Program Type: PGY1 (Pharmacy)
Residency Program Location: Pennsylvania

Co-Author(s): Forrest Ridgway

Primary Author(s)